Organization | BioTeSys GmbH

BioTeSys GmbH Report issue

For profit Phase 1

Founded: Esslingen Germany (1999)

Organization Overview

First Clinical Trial

2011

NCT02548247

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

BioTeSys GmbH | CRO BioTeSys GmbH

Active Ingredients

Drugs in Phase 1 Trials (1)

maltodextrin (1 trial)

Drugs in Other Trials (15)

acacia (1 trial)

aloysia citriodora extract (1 trial)

betahistine mesilate (1 trial)

collagen (1 trial)

fatty acid (1 trial)

glucose (2 trials)

inulin (1 trial)

isomaltulose (1 trial)

lactulose (cephulac) (1 trial)

levocarnitine (carnitor) (1 trial)

mango (2 trials)

omega-3 fatty acids (Omacor) (1 trial)

perilla extract (1 trial)

santa herba (1 trial)

sucrose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Prediabetic State (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 14
# of Trial APIs: 16